Nanopublication: RAV-uYtAmJ

Full identifier: http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RAV-uYtAmJ comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAV-uYtAmJ...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) ""Naratriptan tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1) ] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2) ] History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke [see Warnings and Precautions (5.4) ] Peripheral vascular disease [see Warnings and Precautions (5.5) ] Ischemic bowel disease [see Warnings and Precautions (5.5) ] Uncontrolled hypertension [see Warnings and Precautions (5.8) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)] Severe renal or hepatic impairment [see Use in Specific Populations (8.6, 8.7), Clinical Pharmacology (12.3)] History of coronary artery disease or coronary artery vasospasm (4) Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4) History of stroke, transient ischemic attack, or hemiplegic or basilar migraine (4) Peripheral vascular disease (4) Ischemic bowel disease (4) Uncontrolled hypertension (4) Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan) or an ergotamine-containing medication (4) Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) (4) Severe renal or hepatic impairment (4)"" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAV-uYtAmJ... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-08-23T18:30:22.832+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAV-uYtAmJ... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAhNHZw6Ur... RAhNHZw6Ur .
This is the identifier for this whole nanopublication. http://purl.org/np/RAV-uYtAmJ... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAV-uYtAmJ... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAV-uYtAmJ...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAV-uYtAmJ... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAV-uYtAmJ...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 23 Aug 2021, 16:30:22 UTC

show references